Intelligence Feed event · Policy · 2026-08-27

    FDA Approves Revolution Medicines' RASONQUE as First Broad RAS Inhibitor

    Question

    FDA Approves Revolution Medicines' RASONQUE as First Broad RAS Inhibitor

    Direct answer

    Revolution Medicines received FDA approval for RASONQUE (daraxonrasib), marking the first broad RAS inhibitor cleared for patients with metastatic pancreatic adenocarcinoma. The therapy is designated for individuals who have progressed on prior systemic therapy or cannot receive multiagent chemotherapy. The milestone validates the company's RAS-ON platform architecture following successful Phase 3 RASolute 302 results. Distribution agreements, including a partnership with Onco360, are established to commence distribution.

    Original publisher
    Market Ontology
    Evidence through
    2026-08-27
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “FDA Approves Revolution Medicines' RASONQUE as First Broad RAS Inhibitor”, revision 1, evidence through 2026-08-27. https://marketontology.com/market-events/2026-08-27/fda-approves-revolution-medicines-rasonque-as-first-broad-ras-inhibitor-a16371

    POLICY
    FDA Approves Revolution Medicines' RASONQUE as First Broad RAS Inhibitor
    Revolution Medicines received FDA approval for RASONQUE (daraxonrasib), marking the first broad RAS inhibitor cleared for patients with metastatic pancreatic adenocarcinoma. The therapy is designated for individuals who have progressed on prior systemic therapy or cannot receive multiagent chemotherapy. The milestone validates the company's RAS-ON platform architecture following successful Phase 3 RASolute 302 results. Distribution agreements, including a partnership with Onco360, are established to commence distribution.
    RVMDIMRX
    Impact
    76
    AUG 27
    SIG
    92%
    RVMDIMRX
    FDA Approves Revolution Medicines' RASONQUE as First Broad RAS Inhibitor
    Revolution Medicines received FDA approval for RASONQUE (daraxonrasib), marking the first broad RAS inhibitor cleared for patients with metastatic pancreatic adenocarcinoma. The therapy is designated for individuals who have progressed on prior systemic therapy or cannot receive multiagent chemotherapy. The milestone validates the company's RAS-ON platform architecture following successful Phase 3 RASolute 302 results. Distribution agreements, including a partnership with Onco360, are established to commence distribution.
    → Regulatory commercial authorization unlocks first-line addressable market access and immediate commercial product revenue for RVMD.
    Impact
    Revolution Medicines received FDA approval for RASONQUE (daraxonrasib), marking the first broad RAS inhibitor cleared for patients with metastatic pancreatic adenocarcinoma. The therapy is designated for individuals who have progressed on prior systemic therapy or cannot receive multiagent chemotherapy. The milestone validates the company's RAS-ON platform architecture following successful Phase 3 RASolute 302 results. Distribution agreements, including a partnership with Onco360, are established to commence distribution.
    Affected
    RVMDIMRX
    Transmission
    Regulatory commercial authorization unlocks first-line addressable market access and immediate commercial product revenue for RVMD.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    RVMDdrug commercialization and product revenue de-riskingUpintradayFDA approved RASONQUE for metastatic pancreatic adenocarcinoma.
    IMRXpancreatic oncology competitive landscape repricingMixed1-4wImmuneering reaffirmed focus on first-line pancreatic cancer following the approval.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month